| Trial ID: | L0024 |
| Source ID: | NCT04799925
|
| Associated Drug: |
Febuxostat
|
| Title: |
Hyperuricemia and Diabetic Nephropathy
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Hyperuricemia|Diabetic Nephropathies
|
| Interventions: |
DRUG: Febuxostat
|
| Outcome Measures: |
Primary: Effect of treatment of hyperuricemia on estimated Glomerular Filtration Rate by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation., Number of Participants with type 2 Diabetes Mellitus and stage 3 Chronic Kidney Disease (eGFR: 31:59) will be treated with uric acid lowering drug (febuxostat, 80 mg, once daily) for 6 months to detect the effect of treatment of hyperuricemia on estimated Glomerular Filtration Rate by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation., 6 months from September 2021 to march 2022. |
|
| Sponsor/Collaborators: |
Sponsor: Assiut University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
200
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2021-04-15
|
| Completion Date: |
2022-12-30
|
| Results First Posted: |
|
| Last Update Posted: |
2021-03-16
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT04799925
|
